DRF-1042
CAS No. 200619-13-2
DRF-1042( —— )
Catalog No. M33344 CAS No. 200619-13-2
DRF-1042, an orally active camptothecin analog, exhibits anticancer and insecticidal activities by inhibiting DNA topoisomerase I. It has been studied for its efficacy against solid tumors, including prostate and colon cancers.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 46 | Get Quote |
|
| 5MG | 61 | Get Quote |
|
| 10MG | 101 | Get Quote |
|
| 25MG | 201 | Get Quote |
|
| 50MG | 321 | Get Quote |
|
| 100MG | 506 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameDRF-1042
-
NoteResearch use only, not for human use.
-
Brief DescriptionDRF-1042, an orally active camptothecin analog, exhibits anticancer and insecticidal activities by inhibiting DNA topoisomerase I. It has been studied for its efficacy against solid tumors, including prostate and colon cancers.
-
DescriptionDRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit DNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-agent resistance (MDR) phenotype.
-
In VitroDRF-1042 demonstrates superior lactone stability and good in vitro anticancer activity against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype.
-
In VivoIn clonogenic assay against murine, canine and human bone marrow cells, DRF-1042 treatment shows less mylosupression that supports the possibility of protracted dose schedule in both experimental and clinical studies.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetTopoisomerase
-
RecptorTopoisomerase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number200619-13-2
-
Formula Weight408.4
-
Molecular FormulaC22H20N2O6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (122.43 mM; Ultrasonic )
-
SMILESCC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3C(OCCO)n1c2=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chatterjee A, et al. Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novelcamptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol. 2005 Apr;45(4):453-60.?
molnova catalog
related products
-
Lucidin primeverosid...
Lucidin primeveroside is a natural product isolated from the root powder of akane (Rubia akane) and can be used as a coloring agent and a food pigment. Lucidin primeveroside can be metabolically converted to genotoxic compound Lucidin in mice.
-
Idarubicin hydrochlo...
An anthracycline antileukemic that inserts into DNA and prevents DNA unwinding by interfering with the enzyme Topoisomerase II in cancer cells.
-
Wogonoside
Wogonoside acts as a?positive allosteric modulator?of the?benzodiazepine site of the?GABAA?receptor.
Cart
sales@molnova.com